BioNTech SE has promoted Ryan Richardson to the role of chief strategy officer to help implement the company’s long-term growth strategy. Mr Richardson joined the company in 2018 and previously worked on corporate development. The appointment coincides with BioNTech’s plan to acquire Neon Therapeutics Inc, a US developer of T cell therapies. Mr Richardson previously worked with the healthcare investment banking team at JP Morgan in London where he advised biotech companies on M&A and equity and debt financing. He holds an MBA from the University of Chicago Booth School of Business, an MSc from the London School of Economics and a BS in biology from the University of Kansas, US.
BioNTech announced the appointment on 13 January 2020.
Copyright 2020 Evernow Publishing Ltd.